Ascendis Pharma (ASND) PT Lowered to $326 at Wells Fargo

May 8, 2026 7:29 AM

Wells Fargo analyst Chris M. Carey lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $326.00 (from $330.00) while maintaining a Overweight rating.

No results found